RADNOR, Pa., Dec. 6, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTC BB:PYMX), a clinical-stage biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, is pleased to announce the launch of its redesigned company website at www.polymedix.com. The enhanced site captures the Company's mission to develop innovative and cost-effective drug therapies for life-threatening acute conditions where there is a significant unmet medical need. Additionally, there is extensive information on PolyMedix's two lead products, which are currently being evaluated in Phase 2 clinical studies.
"The new PolyMedix website dynamically expresses our passion to save lives by advancing acute care medicine with innovative drugs that address life-threatening diseases," said Nicholas Landekic, President and CEO of PolyMedix. "Over the last year, PolyMedix has evolved from a research and development company to a mid-stage clinical company. This new website effectively communicates this progress, as well as our strategy for the future."
The redesigned website provides viewers with a comprehensive overview of PolyMedix and extensive background information that is designed to be easy to navigate. With enhanced functionality, including hyperlinks and interactive documents, viewers can delve into various aspects of our clinical development or review multiple scientific data presentations and publications. From the home page, viewers can scan recent news and upcoming events, as well as access featured links to presentations, webcasts, news or data. A new feature of the website is a media tab which highlights PolyMedix in the news. Viewers may visit the investors tab to create a briefcase of regularly viewed files and to subscribe to company updates through email alerts.
About PolyMedix, Inc.
PolyMedix is a clinical stage biotechnology company developing first-in-class, small-molecule drugs for the treatment of serious acute care conditions. PolyMedix has a pipeline of novel infectious disease and cardiovascular product candidates, all of which were internally developed using a proprietary drug discovery platform. The lead compound in PolyMedix's infectious disease program is PMX-30063, a new class of antibiotic – a defensin-mimetic - designed to mimic first-line human innate immunity, or host defense proteins. This innovative approach utilizes the same mechanism of action that evolved in nature which higher life forms use to protect themselves from bacteria. Having the same mechanism of action as the host defense proteins, PMX-30063 is designed to directly address one of the most significant issues in infectious disease today - drug resistance, which is believed to be much less likely to develop with PMX-30063. PMX-30063 is currently in a Phase 2 clinical trial to treat patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by S. aureus bacteria, including methicillin-resistant S. aureus (MRSA). PolyMedix is also leveraging its antimicrobial expertise with the PolyCides®, antimicrobial additives to materials, such as cosmetics, plastics and textiles, to create self-sterilizing products and surfaces. The lead compound in PolyMedix's cardiovascular program is PMX-60056, which is designed to restore coagulation and mitigate bleeding in certain interventional cardiology procedures, such as Percutaneous Coronary Intervention (PCI) and Coronary Artery Bypass Surgery (CABG), as well as treat bleeding in emergency situations. PMX-60056 has met safety and efficacy endpoints in four clinical trials conducted to date demonstrating clinical proof of concept. PMX-60056 is currently in a Phase 2 clinical trial in patients undergoing PCI and in a Phase 1B/2 dose ranging clinical trial in subjects receiving the low molecular weight heparin enoxaparin. For more information, please visit our website at www.polymedix.com.
The PolyMedix, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10449
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are PolyMedix's need for, and the availability of, substantial capital in the future to fund its operations and research and development, and the fact that PolyMedix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.